The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth
- 505 Downloads
Signaling of the receptor for advanced glycation end products (RAGE) has been implicated in the development of injury-elicited vascular complications. Soluble RAGE (sRAGE) acts as a decoy of RAGE and has been used to treat pathological vascular conditions in animal models. However, previous studies used a high dose of sRAGE produced in insect Sf9 cells (sRAGESf9)and multiple injections to achieve the therapeutic outcome. Here, we explore whether modulation of sRAGE N-glycoform impacts its bioactivity and augments its therapeutic efficacy. We first profiled carbohydrate components of sRAGE produced in Chinese hamster Ovary cells (sRAGECHO) to show that a majority of its N-glycans belong to sialylated complex types that are not shared by sRAGESf9. In cell-based NF-κB activation and vascular smooth muscle cell (VSMC) migration assays, sRAGECHO exhibited a significantly higher bioactivity relative to sRAGESf9 to inhibit RAGE alarmin ligand-induced NF-κB activation and VSMC migration. We next studied whether this N-glycoform-associated bioactivity of sRAGECHO is translated to higher in vivo therapeutic efficacy in a rat carotid artery balloon injury model. Consistent with the observed higher bioactivity in cell assays, sRAGECHO significantly reduced injury-induced neointimal growth and the expression of inflammatory markers in injured vasculature. Specifically, a single dose of 3 ng/g of sRAGECHO reduced neointimal hyperplasia by over 70 %, whereas the same dose of sRAGESf9 showed no effect. The administered sRAGECHO is rapidly and specifically recruited to the injured arterial locus, suggesting that early intervention of arterial injury with sRAGECHO may offset an inflammatory circuit and reduce the ensuing tissue remodeling. Our findings showed that the N-glycoform of sRAGE is the key determinant underlying its bioactivity and thus is an important glycobioengineering target to develop a highly potent therapeutic sRAGE for future clinical applications.
The specific N-glycoform modification is the key underlying sRAGE bioactivity
Markedly reduced sRAGE dose to attenuate neointimal hyperplasia and inflammation
Provide a molecular target for glycobioengineering of sRAGE as a therapeutic protein
Blocking RAGE alarmin ligands during acute injury phase offsets neointimal growth
KeywordssRAGE N-glycoform Arterial injury Arterial inflammation Neointimal hyperplasia Therapeutic window
We thank Robert Monticone for rat VSMCs and advice on cell migration assays. We also thank reviewers of this manuscript for their inputs that improve our work. The work was supported by the intramural research program of the NIH, National Institute on Aging (LL, MIT, RPX, and EGL), and the Korea Research Foundation grant KRF-2009-013-E00008 (SP). WW was supported in part by the Oak Ridge Institute for Science and Education’s Research Associates Program at NIH; JP was a recipient of the 2011 Johns Hopkins “Excellent in Medical Student Research Award”; and RAR and DB were supported by intramural research training awards from NIH.
Conflict of interest
NIH has filed a patent based on this work. The authors (SP, WW, R-P X, MIT, EGL, or LL) have not received any royalties from this patent.
- 16.Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275:25781–25790PubMedCrossRefGoogle Scholar
- 18.Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S et al (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097–1109PubMedCrossRefGoogle Scholar
- 21.Varki A, Cummings RD, Esco JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME (2009) Essentials of glycobiology, 2nd edn. Cold Spring Harbor Laboratory, Cold Spring HarborGoogle Scholar
- 29.Tae HJ, Marshall S, Zhang J, Wang M, Briest W, Talan MI (2012) Chronic treatment with a broad-spectrum metalloproteinase inhibitor, doxycycline prevents the development of spontaneous aortic lesions in a mouse model of vascular Ehlers-Danlos syndrome. J Pharmacol Exp Ther 343:246–251Google Scholar